Biomerica, Inc. (NASDAQ:BMRA) Sees Significant Decline in Short Interest

Biomerica, Inc. (NASDAQ:BMRA) was the target of a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 74,357 shares, a decrease of 15.7% from the January 15th total of 88,194 shares. Based on an average daily volume of 17,670 shares, the short-interest ratio is presently 4.2 days. Currently, 3.0% of the company’s shares are sold short. Currently, 3.0% of the company’s shares are sold short. Based on an average daily volume of 17,670 shares, the short-interest ratio is presently 4.2 days.

Institutional Trading of Biomerica

A hedge fund recently raised its stake in Biomerica stock. DRW Securities LLC grew its holdings in shares of Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,925 shares of the company’s stock after buying an additional 6,533 shares during the quarter. DRW Securities LLC owned 0.56% of Biomerica worth $43,000 at the end of the most recent reporting period. Institutional investors own 22.28% of the company’s stock.

Biomerica Stock Up 6.0%

Shares of BMRA opened at $2.29 on Monday. The company has a market cap of $6.92 million, a PE ratio of -2.46 and a beta of 0.19. The business has a fifty day moving average of $2.50 and a 200 day moving average of $2.71. Biomerica has a 52-week low of $2.11 and a 52-week high of $8.80.

Biomerica (NASDAQ:BMRA) last posted its quarterly earnings data on Wednesday, January 14th. The company reported ($0.45) earnings per share for the quarter. The firm had revenue of $1.21 million for the quarter. Biomerica had a negative net margin of 90.29% and a negative return on equity of 83.73%.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.